Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

 Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

Shots:

  • The P-III KEYNOTE-564 evaluating Keytruda monothx (200 mg, IV, on day1 of each 3wks. cycle for up to 17 cycles) vs PBO in 950 patients with RCC, following nephrectomy & resection of metastatic lesions
  • Results: @ median follow-up of 24.1 mos., 32% reduction in the risk of disease recurrence or death, a favorable trend in OS was observed with 46% reduction in risk of death
  • Keytruda is currently approved in the US, EU & Japan in combination with axitinib as a 1L treatment for advanced RCC. The company continues to evaluate the therapy in combination or as monothx across multiple settings & stages of RCC through its broad clinical program include 20 clinical studies & 4,000+ patients

Click here to­ read full press release/ article | Ref: Businesswire | Image: Shutterstock

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post